News

Fierce Pharma11d
In major blow for Lilly, Novo strikes deal giving Wegovy preferred access on CVS Caremark formulary
Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template ...
Novo Nordisk: A Strategy With High Potential For Volatile Times
Novo Nordisk has potential with a 27% upside, strong market shares, and high ROI strategies. See why we recommend a buy on ...
pharmaphorum5h
Novo Nordisk builds case for Norditropin successor
In the REAL8 basket trial, Sogroya (somapacitan), administered as a once-weekly subcutaneous injection, was at least as ...
Healthy Returns: Novo Nordisk’s Wegovy deal with CVS won't derail Eli Lilly's obesity market dominance
Eli Lilly won't lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.
Novo Nordisk Gains as CFO Touts Wegovy’s Rebound Potential
Novo Nordisk A/S shares gained on expectations that competition for its blockbuster obesity shot Wegovy will subside later ...
Down Nearly 20%: Should You Buy the Dip on Eli Lilly?
Sales are booming for Lilly's tirzepatide products, Mounjaro and Zepbound. The company's market share for incretin analogs ...
Novo Nordisk's CFO Sceptical Trump Executive Order on Drug Manufacturing Can Cut Timelines
LONDON/COPENHAGEN (Reuters) -Obesity drugmaker Novo Nordisk's CFO said on Wednesday he was sceptical that U.S. President ...
Jim Cramer on Novo Nordisk (NVO): “Novo Lands Knockout Deal Over Lilly”
We recently published a list of 21 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Novo ...